ABBVEarnings ReleaseSource checkedAugust 3, 2026by InvestLog AI

ABBV earnings release — EPS beat +1.1% · revenue beat +1.1%艾伯维 (ABBV) 财报发布 — EPS 高于预期+1.1% · 营收高于预期+1.1%

Key Results

AbbVie Inc. (ABBV) published results at 2026-07-31 07:47:00.

Actual vs Consensus

EPS: $3.65 vs $3.61 estimate, beat+1.1%.

Revenue: $17.0B vs $16.8B estimate, beat+1.1%.

Profitability and Cash Flow

Period: 2026 Q2 period ended 2026-06-30

Revenue: $17.0B; YoY: +13.3%

Gross profit: $14.4B; Gross margin: 84.7%

Operating income: $6.7B; Operating margin: 39.6%

Net income: $3.6B; GAAP diluted EPS: $2.04

Operating cash flow: $3.8B; Capex: $265M; Free cash flow: $3.6B

Cash: $9.4B; Total debt: $72.9B; Net debt: $63.5B

Official release: AbbVie Reports Second-Quarter 2026 Financial Results

核心结果

艾伯维 (ABBV) 已发布财报，发布时间：2026-07-31 07:47:00。

实际值与市场预期

EPS：$3.65 vs $3.61 预期，高于预期+1.1%。

营收：$17.0B vs $16.8B 预期，高于预期+1.1%。

利润与现金流

期间：2026 Q2 period ended 2026-06-30

营收：$17.0B；同比：+13.3%

毛利润：$14.4B；毛利率：84.7%

经营利润：$6.7B；经营利润率：39.6%

净利润：$3.6B；GAAP 稀释 EPS：$2.04

经营现金流：$3.8B；资本开支：$265M；自由现金流：$3.6B

现金：$9.4B；总债务：$72.9B；净债务：$63.5B

官方公告：AbbVie Reports Second-Quarter 2026 Financial Results

View ABBV stock details ->查看 ABBV 个股详情 ->

This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。

ABBV earnings release — EPS beat +1.1% · revenue beat +1.1%艾伯维 (ABBV) 财报发布 — EPS 高于预期+1.1% · 营收 高于预期+1.1%